IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
10-Q - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
10-Q - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
10-Q - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
10-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is pleased to announce the appointment of Dr. Itzchak Angel as Chief Scientific Advisor.Dr. Angel, in collaboration with Telomir's senior management, will look to expedite the pre-clinical and clinical path of Telomir's lead product candidate, Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process.Telomir is presently optimizing drug production and forming strategic partnersh
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar
4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
3 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
3 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
3 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
3 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity.Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decli
Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business NetworkMIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that the Telomir will be featured on Health Uncensored with Dr. Drew this Sunday, September 29, 2024 at 5:30 PM EST / 2:30 PM PT on Fox Business Network.In this episode, Telomir Pharmaceuticals' Special Advisor, Dr. Michael F. Roizen, MD, Emeritus Chief Wellness Officer at Cleveland Clinic, will join Dr. Drew Pinsky to discuss the science o
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is pleased to announce the appointment of Dr. Itzchak Angel as Chief Scientific Advisor.Dr. Angel, in collaboration with Telomir's senior management, will look to expedite the pre-clinical and clinical path of Telomir's lead product candidate, Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process.Telomir is presently optimizing drug production and forming strategic partnersh
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total mark
TAMPA, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potential treatment for age-related conditions, today announced that its scientific advisor, Adam Kaplin, M.D., Ph.D., was invited by InSilicoTrials to speak on its panel discussion on June 17, 2024, at the DIA Global Annual Meeting. Along with his fellow panelists, Dr. Kaplin will discuss case studies based on his experience using generative AI to provide data modeling solutions to
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines Began geriatric canine study on May 28th with initial dosing of Telomir-1 – All Animals Tolerated Dosing Well – Data will explore the potential for treatment of age-related conditions TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potenti
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces broadcasting of its national business show that will air as a sponsored program on Bloomberg TV on Saturday, May 25, 2024, at 6:30 PM ET. New to The Street airs episode 575 on Bloomberg TV as a sponsored programming Saturday, May 25, 2024, at 6:30 PM ET, featuring the following four (4) corporate interviews: 1). Pharmaceutical - Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) ($TELO) ("Company") interview with Chris Chapman, MD, Co-founder, Chairman, Chief Executive Officer, and Chief Medical Officer. 2). Real Estate - La Rosa Holdings Corp's. (NASDAQ:LRHC) ($LRHC) interviews with Joe La Rosa, Founder
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- FMW Media Works' New to The Street televised business show will feature Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ($TELO) ("Company"), a pre-clinical stage pharmaceutical company, focused on its TELOMIR-1 drug that could reverse age-related common diseases. New to The Street's TV anchors will interview Telomir Pharmaceuticals Inc.'s management team, introducing and discussing the Company's development of its novel TELOMIR-1 drug, designed to affect age reversal. Each filmed segment will air as sponsored programming on Bloomberg TV and the FOX Business Network. The New to The Street's social media team and television network partners will re-sh
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging Demonstrated a 40% increase in telomerase activity and lengthened telomeres in vitro in human cells Provided pre-clinical endpoints to determine "anti-aging" and "age-reversal" effects in dogs Outlined timeline for initiating human investigational new drug (IND) trials for osteoarthritis, along with animal IND (AIND) trials WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on Telo
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines Began geriatric canine study on May 28th with initial dosing of Telomir-1 – All Animals Tolerated Dosing Well – Data will explore the potential for treatment of age-related conditions
Gainers Predictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 18.25% to $0.45. The company's market cap stands at $30.5 million. Telomir Pharmaceuticals (NASDAQ:TELO) stock increased by 12.92% to $7.34. The market value of their outstanding shares is at $217.3 million. NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 11.24% to $2.87. The market value of their outstanding shares is at $30.1 million. TransMedics Gr (NASDAQ:TMDX) shares moved upwards by 11.02% to $104.51. The company's market cap stands at $3.4 billion. As per the press re
Gainers NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's market cap stands at $33.7 million. The company's, Q4 earnings came out 4 days ago. MSP Recovery (NASDAQ:LIFW) shares rose 29.74% to $1.23. The company's market cap stands at $19.5 million. Assure Hldgs (NASDAQ:IONM) stock increased by 24.31% to $0.55. The market value of their outstanding shares is at $4.9 million. ProKidney (NASDAQ:PROK) stock increased by 22.79% to $2.5. The company's market cap stands at $154.3 million. iSpecimen (NASDAQ:ISPC) shares increased by 19.32% to $0.34. The company's market cap stands at $3.1 million. GlucoTrack (NASDAQ:GCTK) stock moved upwards b
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging Demonstrated a 40% increase in telomerase activity and lengthened telomeres in vitro in human cellsProvided pre-clinical endpoints to determine "anti-aging" and "age-reversal" effects in dogsOutlined timeline for initiating human investigational new drug (IND) trials for osteoarthritis, along with animal IND (AIND) trials
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) shares rose 61.6% to $1.83 during Wednesday's regular session. The company's market cap stands at $7.4 million. Jaguar Health (NASDAQ:JAGX) shares rose 32.22% to $0.12. The market value of their outstanding shares is at $32.8 million. Orgenesis (NASDAQ:ORGS) stock rose 27.83% to $0.62. The market value of their outstanding shares is at $21.1 million. BioSig Technologies (NASDAQ:BSGM) shares moved upwards by 15.43% to $1.87. The company's market cap stands at $17.4 million. Etao International Co (NASDAQ:ETAO) shares rose 14.65% to $4.38. The company's market cap stands at $22.4 million. Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 12.84%
Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomeraseNew York Times article supports belief that telomere shortening reduces longevityBALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps in order to potentially address age-related conditions, today announced that anti-aging expert and New York Times bestselling
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on reversing aging in canines
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells The New York Times reports telomere shortening a major contributor to aging
Gainers Aptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 23.65% to $11.92. The company's market cap stands at $211.8 million. Bright Green (NASDAQ:BGXX) stock moved upwards by 20.99% to $0.34. The market value of their outstanding shares is at $62.5 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 14.38% to $1.59. The market value of their outstanding shares is at $55.2 million. Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 13.57% to $8.2. The company's market cap stands at $251.0 million. Annexon (NASDAQ:ANNX) stock mov